Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain

BACKGROUND/OBJECTIVE: AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and sim...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivolo, Simone, Di Fusco, Manuela, Polanco, Carlos, Kang, Amiee, Dhanda, Devender, Savone, Mirko, Skandamis, Aristeidis, Kongnakorn, Thitima, Soto, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589164/
https://www.ncbi.nlm.nih.gov/pubmed/34767564
http://dx.doi.org/10.1371/journal.pone.0259251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589164/
https://www.ncbi.nlm.nih.gov/pubmed/34767564
http://dx.doi.org/10.1371/journal.pone.0259251

Ejemplares similares